Organon's Breast Cancer Treatment Poherdy Receives Positive Opinion from EMA Panel
MT Newswires Live
Feb 27
Organon's (OGN) biosimilar Poherdy was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use for a marketing authorization in breast cancer, the regulator said Thursday.
Poherdy will be available as a 420 mg concentrate for solution for infusion, the agency said. Its active substance is pertuzumab, a monoclonal antibody.
Poherdy has comparable quality, safety and efficacy to Perjeta, which was authorized in the European Union in 2013, the regulator said.
Organon shares were up 2.8% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.